RESEARCH

Hepatitis C reinfection in former and activeInjecting drug users in Belgium

Dana Busschots1,2*, Rob Bielen1,2, Özgür M. Koc1,2,3, Leen Heyens1,2,3, Rita Verrando4, Chantal de Galocsy5, Christophe Van Steenkiste6, Frederik Nevens7, Håvard Midgard8, Olav Dalgard8 and Geert Robaeys1,2,7

Abstract
Background: There is currently no systematic screening for hepatitis C (HCV) reinfection in people who inject drugs (PWID) after treatment in Belgium. However, in a recent meta-analysis, the overall HCV reinfection rate was 5.9/100 person-years (PY) among PWID. Accordingly, this study was undertaken to investigate the reinfection rate in former and active PWID who achieved the end of treatment response after direct-acting antiviral (DAA) treatment in Belgium.

Methods: This observational cross-sectional study recruited individuals with a history of injecting drug use who had achieved the end of treatment response to any DAA treatment between 2015 and 2020. Participants were offered a post-treatment HCV RNA test.

Results: Eighty-five potential participants were eligible to participate and contacted, of whom 60 participants were enrolled in the study with a median age of 51.0 (IQR 44.3–56.0) years; it was reported that 23.3% continued to inject drugs intravenously after DAA treatment. Liver cirrhosis was present in 12.9%. The majority had genotype 1a (51.7%) or genotype 3 (15.0%) infection. We detected no reinfections in this study population. The total time patients were followed up for reinfection in the study was 78.5 PY (median 1.0 years IQR 0.4–2.0).

Conclusion: Reinfection after successful treatment with DAA initially appears to be very low in Belgian PWID. Therefore, efforts should be made to screen individuals with persistent risk behaviors for reinfection systematically. In addition, a national HCV registry should be established to accurately define the burden of HCV infection and reinfection in Belgium and support the elimination of viral hepatitis C in Europe.

Trial registration clinicaltrials.gov NCT04251572, Registered 5 Feb 2020–Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04251572.

Keywords: Reinfection, Hepatitis C virus, People who inject drugs, Direct-acting antivirals

Background
The mortality rate resulting from infection with the hepatitis C virus (HCV) is significant due to complications (e.g., liver cirrhosis and hepatocellular carcinoma) [1]. Approximately 1.0% or 71.1 million (62.5–79.4) people worldwide were chronically infected with HCV in 2015 [2]. The estimated prevalence of HCV antibodies (Ab) and HCV-RNA in Belgium is 0.22% and 0.12%, respectively [3]. These relatively low results are consistent with the Ab prevalence in other Western European countries, particularly in neighboring countries such as France (0.8%), the Netherlands (0.22%), and Germany (0.4%) [4–7]. However, subgroups with higher HCV prevalence exist, and people who inject drugs (PWID) are the most important [8]. A recent study estimated the HCV Ab prevalence in Belgian PWID at 41.1%
similar to data found in France (43.4%), the Netherlands (39.3%), and the UK (49.1%) [4, 9, 10].

The introduction of highly effective direct-acting antiviral (DAA) therapy has changed the HCV treatment paradigm. These changes led to progress toward achieving the World Health Organization’s stated goal of reducing HCV viral infections by 90% (specifically 80% reduction in new HCV cases) and mortality by 65% by 2030 [11, 12]. However, the high list price of DAAAs has led many governments to impose certain reimbursement conditions, such as fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection [13]. DAA regimens have been available in Belgium since 2015 and fully reimbursed for all stage fibrosis since 2019 [14, 15]. However, there are still some restrictions regarding reimbursement of DAA medication. Currently, treatment for HCV is only reimbursed if the patient has a chronic infection (>6 months). However, individuals are infectious even during those first six months and thus can cause ongoing transmission, especially in high-risk groups such as active PWID. Also, DAA treatment can only be prescribed by a hepatologist and is only available in a hospital pharmacy [15].

DAA treatment is also effective in individuals who have received opioid agonist treatment (OAT) and active PWID. Nevertheless, providing HCV care in this population can be challenging because of the loss of follow-up and reinfection after successful treatment in cases of persistent risk behavior [16].

Reinfection is a major concern because it can potentially endanger both the individual and population benefits of HCV treatment. Timely detection of reinfections will also help stop persistent transmission of the virus. In a recent meta-analysis including studies from the DAA era, the overall HCV reinfection rate was 3.9/100 person-years (PY) among PWID [17]. Reinfection data are scarce in Belgium. In 2017, the reinfection rate in one Belgian addiction care center was 2.6/100 PY over a follow-up time of 39 PY [18]. Although it is acknowledged that regular HCV RNA testing after treatment in PWID is an indispensable part of any elimination strategy, the feasibility of monitoring for reinfection and retreatment has been little explored [16]. Also, there is no national HCV registry in Belgium, making it difficult to follow patients after treatment. This study was undertaken to investigate the reinfection rate of HCV in PWID after successful treatment with DAAAs in Belgium. In addition, we wanted to expose the gaps in HCV care in the Belgian PWID population. From these perspectives, recommendations can be made for HCV care post-treatment in other regions.

Methods
Study design and participants
This observational cross-sectional study recruited individuals aged 18 years or older with a history of injecting drug use (IDU) who had achieved the end of treatment response (defined as non-detectable HCV RNA at the end of treatment) to any interferon-free DAA treatment between 2015 and 2020. The study was conducted in three centers. There were two centers in Flanders, one out of hospital drug addiction center and the digestive department of a hospital. The third center, a hepatologist private practice (out of hospital), was in Brussels.

The local researchers of the cooperating centers contacted the potential study participants and invited them to participate in the study between August 2019 and December 2020. A blood draw was done during the study visit for HCV RNA determination. Potential HCV risk factors were assessed through a face-to-face questionnaire on paper in a private and secure setting. The questionnaire was available in Dutch, French, and English and covered a total of 29 questions. Data from the questionnaire included birth gender, year of birth, source of income, level of education, housing in the past six months, history of imprisonment, tattoos or piercings placed in a potentially non-sterile environment, number of unsafe sexual partners, frequency of alcohol use (>14 units per week for women or >21 units per week for men [19]), age of first drug use, kind of drugs injected and when (ever, after DAA treatment), frequency of IDU after (ever, after DAA treatment), having shared paraphernalia, OAT, and needle syringe program (NSP). If available in the medical record, the results of the FibroScan® (cutoffs for HCV: F0–F1 = <7.2 kPa, F2 = 7.2–9.5 kPa, F3 = 9.5–12.5 kPa, F4 = >12.5 kPa) were noted [20].

The ethical committee of Ziekenhuis Oost-Limburg approved the study protocol on August 23, 2018 (18/0012U). The study was conducted following the provisions of the Declaration of Helsinki and its amendments. Good clinical practice guidelines were followed throughout the study, and all participants provided written informed consent [21].

Outcome
Reinfection was defined as HCV RNA recurrence following virologic response at the end of treatment [16]. To optimize the follow-up of reinfection in PWID, the gaps in current care were exposed.

Statistical analysis
The primary outcome was the prevalence (%) of HCV reinfection. Patient demographics were summarized using mean±standard deviation for continuous
characteristics and by proportions for categorical characteristics. All analyses were performed using IBM SPSS Statistics 25.

**Results**

Between August 2019 and December 2020, 85 potential participants were eligible to participate and contacted by the local investigators. Twenty-one individuals could not be contacted and were lost to follow-up (reason unknown), and four individuals had passed away. Sixty (70.6%) individuals were enrolled in the study (Fig. 1).

At the time of inclusion, the median age was 51.0 (44.3–56.0) years, and 81.7% were male. The sociodemographic characteristics of the study population are shown in Table 1.

All participants had a history of IDU, 71.7% (n = 43) received OAT, 21.7% (n = 13) injected drugs during treatment, and it was reported by 23.3% (n = 14) after DAA treatment (Table 2). Among those that injected after treatment, 50.0% (n = 7) reported at least weekly injecting. The most frequently injected drug was heroin (71.4%).

Liver fibrosis scores were available in 96.7% (n = 58), and 12.9% (n = 8) had liver cirrhosis (F4). The majority had genotype 1a (51.7%, n = 31) or genotype 3 (15.0%, n = 9) infection (Table 3).

In this cohort, we detected no reinfections. The total time patients were followed up for reinfection in the study was 78.5 PY (median 1.0 years IQR 0.4–2.0).

**Discussion**

This study evaluated HCV reinfection in 60 PWID in three centers in Belgium. Although about one-quarter of the population had still been actively using drugs, no reinfections were detected in this study group.

Reinfection in PWID after DAA treatment is generally relatively low. In two international, multicenter trials

| Characteristics                                      | N (%)     |
|------------------------------------------------------|-----------|
| Gender                                               |           |
| Male                                                  | 49 (81.7) |
| Female                                               | 11 (18.3) |
| Median age (IQR)                                     | 51.0 (44.3–56.0) |
| Age groups                                           |           |
| < 30                                                 | 2 (3.3)   |
| 30–39                                                | 5 (8.3)   |
| 40–49                                                | 19 (31.7) |
| 50–59                                                | 31 (51.7) |
| ≥ 60                                                 | 3 (5.0)   |
| Birth country                                        |           |
| Belgium                                              | 51 (85.0) |
| Other                                                | 9 (15.0)  |
| Income                                               |           |
| Employed                                             | 12 (20.0) |
| Temporary benefit (unemployed)                       | 15 (25.0) |
| Temporary benefit (disability)                       | 31 (51.7) |
| Retirement                                           | 1 (1.7)   |
| No income                                            | 1 (1.7)   |
| Education                                            |           |
| Completed primary                                    | 13 (21.7) |
| Partly high school                                   | 25 (40.0) |
| High school                                          | 18 (30.0) |
| University/college                                   | 5 (8.3)   |
| Housing                                              |           |
| Owned/rented                                         | 48 (80.0) |
| Residential                                          | 3 (5.0)   |
| Family/friends                                       | 8 (13.3)  |
| Homeless                                             | 1 (1.7)   |
| Household member with HCV                            |           |
| Yes                                                  | 13 (21.7) |
| No                                                   | 47 (78.3) |
| History of imprisonment                              |           |
| Yes                                                  | 41 (68.3) |
| No                                                   | 19 (30.6) |
| Potentially non-sterile tattoo/piercing              |           |
| Yes                                                  | 28 (46.7) |
| No                                                   | 32 (53.3) |
| Unsafe sexual contacts                                |           |
| Yes                                                  | 59 (98.3) |
| No                                                   | 1 (1.7)   |
| Number of unsafe sexual contacts                     |           |
| 1–5                                                  | 12 (20.3) |
| 6–10                                                 | 10 (16.9) |
| > 10                                                 | 15 (25.4) |
| Missing                                              | 22 (37.3) |
| Alcohol abuse                                         |           |
| Never                                                | 9 (15.0)  |
| In the past                                          | 15 (25.0) |
| < Monthly                                            | 14 (23.3) |
| < Weekly                                             | 6 (10.0)  |
| > Weekly                                             | 6 (10.0)  |
| Daily                                                | 10 (16.7) |
Busschots et al. Harm Reduct J          (2021) 18:102

(SIMPLIFY and D3FEAT), participants were enrolled at 25 sites in Australia, Canada, France, New Zealand, Norway, Switzerland, the UK, and the USA. The researchers observed a reinfection prevalence of 4.5% and an overall reinfection rate of 3.1/100 PY [22]. In a recent study in Norway, the prevalence of HCV reinfection was 2.7% (8/297) and the incidence 2.60/100 PY (95% CI 1.12–5.11)[16]. Also, in Scotland, reinfection in people living with HIV (80% PWID) appears to be notably low, with an incidence of 0.2/100 PY [23]. In a recent meta-analysis including studies from the DAA era, the overall HCV reinfection rate was 5.9/100 PY (95% CI 4.1–8.5) among PWID [17]. However, we must keep in mind that the reinfection rate depends on the context. It may depend on how quickly DAA treatment is scaled up and the proportion of the high-risk population that receives treatment [24]. Large, high-quality multicenter studies are needed to get an accurate overview of this problem.

Our findings are also lower than data from previous Belgian studies. In one study, the prevalence was 2.8%, and the incidence was 2.6/100 PY. However, this study was monocentric and with a limited number of inclusions (36 participants, one reinfection) and a shorter follow-up time (39 PY)[25]. Nevertheless, there were two previously detected reinfections (personal communication; [17]). We thus arrive at a prevalence of 2.8% with two reinfections in 71 patients after treatment with a sustained virologic response in the province of Limburg, Belgium. However, we have insufficient data to calculate the exact incidence. The incidence in another (monocentric) study with five reinfections was 0.5/100 PY which is an exceptionally low incidence given that 60.0% had injected drugs after treatment [26]. However, similar to our findings, the mean age in this cohort was also 51 years which could partially explain the low reinfection rates. Studies have shown that younger individuals had higher reinfection rates, potentially due to higher rates of risk behavior (e.g., needle sharing) [16, 27]. In addition, the low reinfection prevalence in our study could also be explained by the fact that recent IDU was low (23.3%), and daily injection was even completely absent. This finding is not surprising since most of the participants are from rural areas (province of Limburg). In rural settings, the frequency of injecting use is often lower than in a (metropolitan) city [28]. In addition, in the meta-analysis of Hajarizadeh et al., recent IDU varied between 17.0 and 100%, and in the Norwegian study and the study of Cunningham et al., recent IDU was remarkably high, 70.1% and 73.0%, respectively [16, 17]. Furthermore, we

### Table 1 (continued)

| Characteristics | N (%) |
|-----------------|-------|
| 'Unsafe' refers to sexual contact without the use of a condom | |
| IQR, interquartile range; HCV, hepatitis C virus | |

### Table 2 Characteristics concerning injecting drug use (n = 60)

| Characteristics | N (%) |
|-----------------|-------|
| Median age first drug use (IQR) | 18.0 (16.0–21.0) |
| OAT | 43 (71.7) |
| NSP | 45 (75.0) |
| Ever heroin | 55 (91.7) |
| Ever amphetamines | 7 (11.7) |
| Ever cocaine | 28 (46.7) |
| Ever shared a needle | 45 (75.0) |
| IDU during DAA | 13 (21.7) |
| IDU after DAA | 14 (23.3) |
| Heroin | 10 (17.1) |
| Amphetamine | 3 (21.4) |
| Cocaine | 4 (28.6) |
| How often IDU after DAA (n = 14) | |
| Less than weekly | 7 (50.0) |
| More than weekly, not daily | 7 (50.0) |
| Daily | 0 |
| Shared a needle after DAA (n = 14) | 7 (50.0) |
| Frequency (n = 7) | |
| Once/twice | 4 (57.1) |
| Sometimes | 3 (42.9) |

| Characteristics | N (%) |
|-----------------|-------|
| IQR, interquartile range; IDU, intravenous drug use; OAT, opioid agonist therapy; NSP, needle syringe program; DAA, direct-acting antivirals | |

### Table 3 Medical characteristics of the participants

| Characteristics | N (%) |
|-----------------|-------|
| HIV coinfection | 0 |
| Fibrosis | |
| F0–F1 | 27 (43.5) |
| F2 | 12 (19.4) |
| F3 | 13 (21.0) |
| F4 | 8 (12.9) |
| Missing | 2 (3.2) |
| Genotype | |
| 1a | 31 (51.7) |
| 1b | 7 (11.7) |
| 3 | 9 (15.0) |
| 4 | 5 (8.3) |
| Missing | 8 (13.3) |
| Year end of treatment | |
| 2015 | 1 (1.7) |
| 2016 | 6 (10.0) |
| 2017 | 7 (11.7) |
| 2018 | 9 (15.0) |
| 2019 | 30 (50.0) |
| 2020 | 7 (11.7) |

| Characteristics | N (%) |
|-----------------|-------|
| IQR, interquartile range | |
| NSP, needle syringe program | |
| DAA, direct-acting antivirals | |
suspect that we were unable to reach those at the highest risk (active injectors) because they were unable to contact them, and the follow-up period was relatively short.

The literature states that reinfection is slightly lower in users receiving opioid agonist therapy (OAT) with an incidence of 3.8/100 PY (95% CI 2.5–5.8) [17]. In a study at an OAT clinic in the Bronx, New York, a reinfection prevalence of 2.1% and a reinfection rate of 1.2/100 PY were measured in PWID who received OAT [29]. The absence of reinfection in our cohort may reflect the relatively short follow-up time and the effect of an integrated model of care with good access to OAT and NSP, combined with high reinfection awareness among study participants. OAT and NSP coverage in our cohort was high, respectively, 71.7% and 75.0%, and similar to other European countries [16, 17]. These findings align with Hajarizadeh et al. and Rossi et al., who showed a lower reinfection risk among people receiving OAT [17, 30].

Besides, there is no systematic screening or follow-up for reinfection in high-risk groups. As Midgard et al. showed in their study, reinfection surveillance and retreatment in a real-world PWID cohort is feasible [16]. Although this is a single-center study, it is questionable whether this is feasible on a national level. This brings us to one of the major shortcomings in terms of HCV care in Belgium, the lack of a national registry for HCV. A national registry could map the progression to elimination as all initiatives are currently at a local level. This could drastically reduce the lost-to-follow-up and provide the opportunity for concrete monitoring of patients. For proper follow-up of patients after treatment, not only a national registry but also an HCV case manager is essential. Follow-up by an HCV case manager is beneficial not only for follow-up of reinfection but also for liver cirrhosis. This is equally important, especially since we observe that liver cirrhosis is present in 12.9% in this group. The case manager can work closely with addiction care centers and hepatologists in a hospital. In Limburg, Belgium, the zorGGroep Zin has been working with an HCV case manager since 2015. This has dramatically increased the rate of screening, treatment, and follow-up after treatment [31]. Consequently, the lack of a specific person focusing solely on HCV care was probably the main reason for not participating in this study due to the high workload of the current staff.

This study had several limitations. First, we did not actively follow this group. As a result, spontaneous clearances could not be detected, and we, therefore, underestimated the actual burden. Moreover, it was a cross-sectional study. As a result, we were unable to calculate the PY of follow-up correctly. Although we had the end of treatment date, we could not be sure if the individual had been tested in the meantime, which led to the fact that we could only report the reinfection prevalence. Given the small number of participants, these data may not be generalizable to all PWID in Belgium. Furthermore, the inclusion rate is subject to the COVID measures in place in Belgium since March 13, 2020. As a result, regular care was drastically reduced, and scientific studies were temporarily put on hold. Another fact that has had a negative impact on our inclusion rate is the lack of a national register. This is not in line with HCV elimination, as we cannot provide accurate national data. We must also consider selection bias. Individuals could choose to participate in this study. Therefore, it is possible that active users with a high-risk profile did not participate. In addition, data were also not collected from individuals who declined to participate or from those who were lost to follow-up. This potential selection bias may also have contributed to the fact that we did not find any reinfection in this relatively small population. As mentioned earlier, there are indeed reinfections in the Belgian PWID population regardless of the very low prevalence. Furthermore, analyses could not be performed to identify potential risk factors due to the absence of reinfections. Next, HCV RNA testing by finger prick using a point-of-care molecular testing (POCT) instrument is currently not approved as a diagnostic tool in Belgium. However, the instrument has recently been validated in a population of Belgian PWID [32]. On top of that, currently, finger prick tests can only be performed by medical professionals (e.g., physicians and nurses). Instead, these finger prick tests are best performed by nonmedical professionals, such as social workers and peer supporters, as they are the ones who can reach at-risk populations in a very low-threshold manner.

Conclusion
Reinfection after successful treatment with DAA initially appears to be very low in Belgian PWID. Nevertheless, efforts should be made to systematically screen persons with persistent risk behavior for reinfection since about one-quarter still show risk behavior after treatment. Screening for reinfection should be optimized by adjusting reimbursement for HCV RNA testing, recognizing POCT as a diagnostic tool, and legalizing the use of POCT by nonmedical professionals. In addition, a national HCV registry should be established to accurately define the burden of HCV infection and reinfection in
Belgium and support the elimination of viral hepatitis C in Europe.

Abbreviations
HCV: Hepatitis C virus; Ab: Antibody; PWD: People who inject drugs; DAA: Direct-acting antivirals; OAT: Opioid agonist treatment; IDU: Injecting drug use; NSP: Needle syringe program; IQR: Interquartile range; PCOT: Point-of-care molecular testing.

Acknowledgements
The Ph.D. author is part of the ‘Limburg Clinical Research Center (LCRC), supported by the foundation Limburg Sterk Mek, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg, and Jessa Hospital. Special thanks to Eefje Dercon and Nina Van Hedegem for their contribution to data management. D.B., FN, and GR are part of the project G0B2317N funded by the Fund of Scientific Research-Flanders (FWO).

Authors’ contributions
DB, RB, and GR designed the study. DB, Cdg, and CVS collected the data. DB conducted the statistical analyses. DB drafted the first version of the paper. All co-authors made a substantial contribution to interpreting data, critically revised the article, and approved the final version, including the authorship list. All authors read and approved the final manuscript.

Funding
This project has been made possible thanks to an unrestricted Grant (V-2911) by Gilead Sciences registered at Hasselt University. No direct benefits were granted to the pharmaceutical industry.

Availability of data and materials
The data supporting the conclusions of this article are included within the article.

Declarations
Ethical approval and consent to participate
The ethical committee approved the study protocol of Ziekenhuis Oost-Limburg on August 23, 2018 (18/0012U). The study protocol is registered at clinicaltrials.gov (NCT04251572). The study was conducted in accordance with the provisions of the Declaration of Helsinki and its amendments. Good clinical practice guidelines were followed throughout the study and all participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
DB has received travel grants from AbbVie and Gilead Sciences and research grants from Gilead Sciences; RB has received travel grants from AbbVie, Gilead Sciences and Merck Sharp & Dohme (MSD) and research grants from Gilead and MSD, OK has received a travel grant from Gilead Sciences and research grants from Gilead Sciences and CyTulVax BV; FN has received research grants, consultancy agreements and travel grants in relationship with this manuscript from AbbVie en Gilead; MH has received advisory boards fees and lecture fees from Gilead, AbbVie, and MSD; OD has received research support from AbbVie, Gilead and MSD/MERCK; GR has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and consultancy agreements for AbbVie, BMS, Gilead Sciences and MSD. All other co-authors report no competing interests.

Author details
1Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, Diepenbeek, 3500 Hasselt, Belgium. 2Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium. 3School of NUTRIM, Maastricht University Medical Centre, Maastricht, The Netherlands. 4ziorgGroep Zin, Hasselt, Belgium. 5Private practice, 1190 Brussels, Belgium. 6Department of Gastroenterology and Hepatology, AZ Middelare, Gent, Belgium. 7Department of Gastroenterology and Hepatology, University Hospitals KU, Leuven, Belgium. 8Department of Infectious Diseases, Akerhus University Hospital, Lørenskog, Norway.

Received: 14 July 2021 Accepted: 27 September 2021
Published online: 12 October 2021

References
1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553–62.
2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.
3. Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyldermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, et al. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. BMC Public Health. 2019;19(1):39.
4. ECDC. Systematic review on hepatitis B and C prevalence in the EU/EEA. In: Control ECO DPa. Stockholm: European Centre for Disease Prevention and Control, 2016.
5. Vriend HJ, Van Veen MG, Prins M, Urbanus AT, Boot HJ. Op De Coul SL: Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect. 2013;141(6):1310–7.
6. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antonia D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82(4):546–55.
7. Han R, Zhou J, François C, Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis. 2019;19(1):655.
8. Arai A, De Sousa J, Corten K, Verrando R, Thijs H, Mathei C, Buntinx F, Robaey G. Pilot study: combining formal and peer education with fibrescan to increase HCV screening and treatment in persons who use drugs. J Subst Abuse Treat. 2016;67:44–9.
9. Van Baelen L, Pleitnick E, Antoine J, Gremaeus L. Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sample survey. Harm Reduct J. 2020;17(1):11.
10. Leon L, Kasreka S, Barin F, Larsen C, Weill-Barrier L, Pascal X, Chevalleau S, Pillonel J, Jauffret-Rostuide M, Strat LE, Y. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004–2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2017;145(5):889–907.
11. WHO. Global Hepatitis Report, 2017. Geneva: World Health Organisation; 2017.
12. WHO. Global health sector strategy on viral hepatitis 2016–2021, vol. WHO/HIV/2016.06. Geneva: World Health Organisation; 2016.
13. Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgaard O, Seguin-Devaux C, Flisiak R, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125–33.
14. Recente informatie januari 2015: tapentadol, alemtuzumab, simeprevir en sofosbuvir. http://www.bfct.be/nl/articles/2271foliaaspx.
15. Antivirale geneesmiddelen tegen hepatitis C: vergoedingsvoorwaarden vanaf 1 januari 2019. https://www.rivz/gov/be/nl/themas/kost-terugbetal/ing/door-ziekenfonds/geneesmiddel-gezondheidsproduct/terugbetal/en/specialiteiten/wijzigingen/Paginas/antivirale-hepatitis-terugbetaling/voorwaarden_20190101.aspx.
16. Midgard H, Ulstein K, Backe Ø, Foshaug T, Sarli H, Vennesland K, Nilsen D, Dahl EH, Finbråten AK, Wusthoff L, et al. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. Int J Drug Policy. 2021. https://doi.org/10.1016/j.drugpo.2021.103165.
17. Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgaard D, Dillon J, Hickman M, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(6):643–57.
18. Bielen R, Dercon E, Koc OM, Busschots D, Vinken L, Verrando R, Vanhees K, Nevens F, Robaeys G. Hepatitis C nurse as a case manager in people who inject drugs. In: AASLD, San Francisco; 2018.
19. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154–81.
20. Quantifying fibrosis with FibroScan. https://www.echosens.com/en/myfibroscan-smart-app-to-manage-chronic-liver-diseases.
21. Tripartite Guideline for Good Clinical Practices E6 (R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
22. Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P et al. Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs. Clin Infect Dis. 2020.
23. Byrne C, Robinson E, Rae N, Dillon JF. Toward microelimination of hepatitis C and HIV coinfection in NSW Tayside, Scotland: real-world outcomes. Health Sci Rep. 2020;3(4):e191.
24. Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14(1):641–51.
25. Case Management in HCV Infected PWID (CM-HCV) (ClinicalTrials.gov Identifier: NCT03106194). https://clinicaltrials.gov/ct2/show/NCT03106194.
26. Mathi C. Progress towards hepatitis C elimination. In: NHSSU 2019, Montreal, Canada, 2019.
27. Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, Wong J, Tyndall MW, Janjua NZ, Team BCTCB-H. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet Gastroenterol Hepatol. 2017;2(3):200–10.
28. Day C, Conroy E, Lowe J, Page J, Dolan K. Patterns of drug use and associated harms among rural injecting drug users: comparisons with metropolitan injecting drug users. Aust J Rural Health. 2006;14(5):120–5.
29. Akiyama MJ, Lipsey D, Heo M, Agyemang L, Norton BL, Hidalgo J, Lora K, Litwin AH. Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy. Clin Infect Dis. 2020;70(12):2695–702.
30. Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, Darvishian M, Gilbert M, Wong J, Chapinal N, et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol. 2018;69(5):1107–14.
31. Bielen R, Verrando R, Penders J, Oris E, Nevens F, Robaeys G. Case management to improve uptake for screening and therapy of hepatitis C viral infection in people who inject drugs. In: AASLD, Boston; 2016.
32. Bielen R, Koc OM, Busschots D, Verrando R, Nevens F, Robaeys G. Validation of hepatitis C virus RNA detection using capillary blood by fingerprick (GenXpert system)-Hepatitis C fingerprick study. J Viral Hepat. 2020;27:709–14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.